Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: July 24, 2025
Reporting Period: Event-based report regarding upcoming clinical trial data presentation.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report focused on a corporate event rather than financial performance.
Material Changes
No material financial changes are reported in this filing. The primary event is the announcement of additional analyses from the Phase 2 MINDFuL trial evaluating XPro®, a novel selective soluble tumor necrosis factor inhibitor.
Guidance, Outlook, and Management Commentary
- Upcoming Event: Oral presentation of additional Phase 2 MINDFuL trial data.
- Conference: Alzheimer's Association International Conference.
- Location: Toronto, Canada.
- Date and Time: Tuesday, July 29, 2025, between 2:00 and 3:30 PM ET.
- Management Commentary: The filing incorporates a press release (Exhibit 99.1) but does not provide specific commentary on the trial results within the text of the 8-K itself.
Investor Verification Checklist
- Verify the content of the press release filed as Exhibit 99.1 for specific details on the XPro® trial analyses.
- Monitor the oral presentation at the Alzheimer's Association International Conference on July 29, 2025, for clinical data updates.
- Review subsequent filings for any financial impact or strategic shifts resulting from the trial data.